For the Inventor, By the Inventor

Enter assignee name

Riken Corporation

USPTO Granted Patents = 889

% Expired Patents = 45.6

CIPO Patents = 16

EPO Patents = 274

Forward Citations = 3,006

Loading Chart...

Loading Chart...

1,652 inventors (with patents filed for the assignee):

Hideki Hirayama (44 out of 46 patents)

Shigeyuki Yokoyama (44 out of 54 patents)

Yoshiki Sasai (37 out of 37 patents)

4. Atsushi Miyawaki (37 out of 45 patents)

5. Satoshi Wada (20 out of 33 patents)

6. Hideo Yokota (19 out of 20 patents)

7. Kiwamu Kase (19 out of 21 patents)

8. Zhaomin Hou (18 out of 18 patents)

9. Hitoshi Ohmori (18 out of 34 patents)

10. Hiroyuki Osada (17 out of 22 patents)

11. Yoshihide Hayashizaki (17 out of 54 patents)

12. Masayo Takahashi (16 out of 19 patents)

13. Yoshinori Tokura (16 out of 36 patents)

14. Satoshi Karasawa (16 out of 25 patents)

15. Masaru Taniguchi (15 out of 22 patents)

Core Competencies:

Retinal Tissue

Ophthalmic Devices

Infection Prevention

Stem Cells

Pharmaceutical Composition

Optical Devices

Radiation Dosimetry

Nondestructive Inspection

Biological Material

Gas Detection

Superconducting Devices

Magnetic Resonance

889 patents: Sort by Forward Citations

1. 12753213 - NOVEL POLYPEPTIDE EXHIBITING FLUORESCENT PROPERTIES AND USE FOR SAME (2026-10-06),

2. 12750943 - Radio frequency quadrupole linear accelerator, neutron source system, and radio frequency quadrupole linear accelerator manufacturing method (2026-09-29),

3. 12735693 - METHOD FOR PRODUCING CHAIN UNSATURATED CARBOXYLIC ACID COMPOUND USING PHENYLALANINE AMMONIA LAYSE (2026-09-15),

4. 12704816 - Physical package for optical lattice clock (2026-08-11),

5. 12703867 - CELL CAPABLE OF ACTIVATING IMMUNE SYSTEM, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL (2026-08-11),

6. 12697805 - Propulsion strengthening member (2026-08-04),

7. 12697384 - MULTIPLE ANTIGENIC PEPTIDE AGAINST CORONAVIRUS AND IMMUNOSTIMULATING COMPOSITION CONTAINING THE SAME (2026-08-04),

8. 12696570 - Light-receiving device, X-ray imaging device, and electronic apparatus (2026-07-28),

9. 12679805 - Bioactive substance exhibiting antimalarial activity, and use for same (2026-07-14),

10. 12670235 - Classification device, classification method, program, and information recording medium (2026-06-30),

11. 12669496 - Method for evaluating and/or screening a control agent for tissue morphology and/or tissue function (2026-06-30),

12. 12655378 - Cell culture container, fixing tool, observation device, microscope and observation method (2026-06-16),

13. 12648693 - Ophthalmic information processing apparatus, ophthalmic apparatus, ophthalmic information processing method, and recording medium (2026-06-09),

14. 12648688 - Medical system and medical method (2026-06-09),

15. 12644203 - NOVEL CELLULAR PHENOTYPE SCREENING METHOD (2026-06-02),

Company Overview

Riken Corporation, headquartered in Saitama, Japan, specializes in retinal tissue engineering and the development of advanced ophthalmic devices. The company focuses on innovative solutions that integrate stem cell technology and pharmaceutical compositions to enhance vision care. Riken is also engaged in research related to infection prevention and optical devices, contributing to the fields of radiation dosimetry and nondestructive inspection. Their commitment to cutting-edge technology positions them as a leader in the medical and optical sectors.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

889 Patents

#5 in Saitama 343-0827

#248 in Japan

#1,140 in the World

Riken Corporation

Forward Citations = 3,006

1,652 inventors:

Hideki Hirayama (44 out of 46 patents)

Shigeyuki Yokoyama (44 out of 54 patents)

Yoshiki Sasai (37 out of 37 patents)

4. Atsushi Miyawaki (37 out of 45 patents)

5. Satoshi Wada (20 out of 33 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Riken Corporation. Retrieved from https://idiyas.com/company/riken

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…